Sinovac steps up defense of shot after confusing data

According to China’s Sinovac Biotech Ltd., “the vaccine’s ability to protect medical workers in active outbreaks could significantly improve if they are administered between 21 or 28 days.” — Image via Governo do Estado de São Paulo/Flickr/CC BY 2.0

China’s Sinovac Biotech Ltd. defended the efficacy of its coronavirus disease 2019 (COVID-19) shot, saying the vaccine that’s being rolled out from Indonesia to Brazil despite inconsistent data readouts is more effective in preventing the disease if the two-dose regime is administered over a longer time frame.

Nearly 1,400 of the 13,000 people who took part in clinical trials of Sinovac’s vaccine, called CoronaVac, received their doses three weeks apart, while most of the volunteers in the Brazil-based trials got the second jab two weeks after the first. The protection rate for the smaller group was nearly 20 percentage points higher than the 50.4% rate observed in the majority, Sinovac said in a written response to Bloomberg News.

The comments come after CoronaVac delivered vastly different efficacy rates in four clinical trial sites, fueling concern over whether the vaccine that’s key to the inoculation campaigns of some of the world’s COVID hotspots will be effective in stemming outbreaks. Indonesia’s President Joko Widodo got the vaccine on national TV last week, while Brazil, home to the world’s third-biggest coronavirus outbreak, authorized it for emergency use on Sunday.

In its response, Sinovac also reiterated that the participants in its Phase III trial in Brazil—the largest one for CoronaVac undertaken worldwide—were medical workers who tended to COVID patients, arguing they faced higher exposure to the highly infectious pathogen.

“The vaccine’s ability to protect medical workers in active outbreaks could significantly improve if they are administered between 21 or 28 days,” the company said in its statement to Bloomberg.

Shots developed by Pfizer Inc. and Moderna Inc. that are now being administered around the world generated much higher efficacy rates of more than 90% in final-stage trials that included a more diverse range of people, according to the companies’ statements. Sinovac earlier indicated the prevalence of medical workers in its Brazil trial was why the efficacy rate was so low.

An experimental shot must be at least 50% effective in preventing symptomatic COVID-19 to be approved for general use, a threshold widely held by major drug regulators around the world and the World Health Organization.

The fresh details provided by Sinovac indicate CoronaVac could be more than borderline effective in preventing the disease from taking hold in those who take it, but also risk adding to the general confusion around the shot. Trials in Indonesia and Turkey delivered efficacy rates ranging from 65% to more than 90% but have been deemed largely inconclusive because of the small number of participants and fewer COVID cases involved.

The rate described for the smaller group in Brazil would put the vaccine on par with results seen for the shot co-developed by AstraZeneca Plc and the University of Oxford, which is being deployed in places like India.


As vaccines are rolled out more broadly, greater attention is being paid to dose intervals and whether the time between shots plays a role in the immune response among vaccinated people.

Yang Xiaoming, chairman of the other Chinese Covid vaccine frontrunner, China National Biotec Group Co., said in an interview with the state-run news agency Xinhua last week that its vaccine—which is already approved in China for general use—could generate more lasting immunity and higher levels of antibodies if given three or four weeks apart, compared with one or two weeks.

Earlier this month, the US Food and Drug Administration pushed back after a key health official suggested cutting dosage levels could be a way to immunize more people more quickly. The agency urged that vaccines be given according to how the FDA authorized them, saying changes may not guarantee the high level of protection observed in trials and risk endangering public health.


Despite the inconsistencies in its publicly announced efficacy rates, CoronaVac continues to be approved for use, with Brazil the latest country to endorse its administration on an emergency basis. Turkey authorized Sinovac’s shot on Jan. 13 and it was given to President Recep Tayyip Erdogan, according to the company.

Chile, the Philippines, Thailand, Hong Kong, and Singapore also have deals or agreements to buy and distribute CoronaVac. Regulators in the Philippines and Hong Kong have asked for more complete data before receiving their shipments. Hong Kong, where a panel of experts on Monday recommended the Pfizer vaccine be approved for use, plans to offer people a choice of which shot to take.

Meanwhile, Sinovac is submitting data for review in its home country, where the regulator endorsed CoronaVac for emergency use in July and is expected to rule soon on its viability for broader, general use. China’s National Medical Products Administration uses a slightly different standard to define COVID-19 cases in trials, which could lead to yet another efficacy rate for the shot.

The Chinese regulator’s definition of COVID-19 in clinical trials is a CT scan showing legions in the lung, or two atypical or one typical symptom for more than two days, plus a nucleic acid test detecting the virus in samples. The Brazilian trial protocol, however, only requires a positive nucleic acid test result and any symptoms lasting more than two days, according to a diagram Sinovac provided to Bloomberg. — Bloomberg

Leave a Reply

Your email address will not be published. Required fields are marked *